Key Takeaways
- Vireo Growth Inc. (CSE: VREO) has entered into a definitive agreement to acquire all issued and outstanding shares of C21 Investments Inc. (CSE: CXXI) in an all-share transaction, at an exchange ratio of 0.023052 Vireo shares per C21 share.
- The acquisition is expected to grow Vireo's Nevada dispensary count to approximately 15 locations and add around 158,000 square feet of combined cultivation and manufacturing capacity in the state.
- C21 brings three of the highest-volume dispensaries in Nevada, along with its Silver State Relief brand, which Vireo describes as a leading northern Nevada operation.
- The C21 Board unanimously approved the transaction following a recommendation from a special committee, supported by an independent fairness opinion from Needham & Company, LLC.
- A shareholder vote is expected at a C21 meeting in Q3 2026, with closing subject to court, regulatory, and customary conditions. A termination fee of US$3 million is payable by C21 in certain circumstances.
Vireo Growth to Acquire C21 Investments in All-Share Deal
Vireo Growth Inc. (CSE: VREO; OTCQX: VREOD) has announced a definitive arrangement agreement to acquire C21 Investments Inc. (CSE: CXXI; OTCQX: CXXIF) through an all-share transaction. Under the terms of the deal, each C21 shareholder will receive 0.023052 of a Vireo subordinate voting share for every C21 share held. C21 will be delisted from the Canadian Securities Exchange and the OTCQX Market upon closing, and C21 will apply to cease reporting issuer status under applicable Canadian and U.S. securities laws.
The transaction adds C21's vertically-integrated Nevada cannabis operations to Vireo Growth's existing multi-state platform, which currently spans 10 states across the U.S. C21's assets include cultivation, manufacturing, and retail operations concentrated in northern Nevada, where its Silver State Relief brand holds a recognized position in the U.S. cannabis market.
“This acquisition further expands our presence in Nevada, an important market for us, and strengthens our ability to serve customers across the state. C21 adds a leading northern Nevada operation to our existing platform, including three of the highest volume dispensaries in the state with its award-winning Silver State Relief brand. This Transaction further extends our leading market share in Nevada and is expected to generate meaningful synergies for the business. C21 has built a highly respected business with its loyal customer base, quality brands and operational efficiency, making them a natural fit for Vireo. We are excited to welcome the C21 team and look forward to building on their success as we continue to execute our growth strategy and deliver for our shareholders,” said John Mazarakis, Chief Executive Officer of Vireo Growth.
Nevada Footprint to Expand to 15 Dispensaries
Upon closing, Vireo Growth expects to operate approximately 15 dispensaries in Nevada, with combined cultivation and manufacturing capacity of around 158,000 square feet in the state. The addition of C21's three high-volume northern Nevada dispensaries would strengthen Vireo's geographic coverage across the state's key retail markets and extend what the company describes as its leading Nevada market position.
C21's Chairman, Bruce Macdonald, framed the deal as the outcome of a thorough strategic review process.
“After a thorough evaluation of strategic options, the C21 Board determined that this Transaction represents a highly attractive opportunity for our shareholders and positions the business for continued success as part of Vireo's leading cannabis platform in Nevada. Vireo shares our strategic vision and core values, and has a proven track record of M&A success. Vireo brings the necessary scale, access to capital and broad market reach that we believe will be critical as the US cannabis industry continues to evolve and grow. We are excited about the opportunities this combination creates and have tremendous confidence in John's leadership, Vireo's strategic direction, and the long-term growth potential of the organization,” said Bruce Macdonald, Chairman of C21 Investments.
Vireo Growth's Strategic Rationale for the Deal
Vireo Growth positions the C21 acquisition as consistent with its broader approach to building scale through M&A in key U.S. cannabis markets. The company currently operates across 10 states and has previously completed multiple acquisitions. The addition of C21 is expected to generate operational synergies through shared infrastructure and supply chain efficiencies across a larger combined Nevada platform.
For C21, the transaction provides access to the capital and multistate distribution reach of a larger operator at a time when the U.S. cannabis industry remains in a period of consolidation. The combination is structured to allow C21's brand and operations to continue under the Vireo umbrella while gaining exposure to a well-capitalised multi-state platform.
Approvals, Timeline, and Closing Conditions
The C21 Board unanimously approved the transaction, with interested directors abstaining from the vote, following a recommendation from a special committee that conducted a comprehensive review with independent financial and legal advisors. Needham & Company, LLC provided an independent fairness opinion confirming the consideration is fair to C21 shareholders from a financial point of view. The Vireo Growth board also unanimously approved the deal.
Closing requires approval from at least two-thirds of votes cast by C21 shareholders at a meeting expected in Q3 2026, plus court and regulatory approvals. Certain C21 directors and officers have entered into voting support agreements committing their shares in favour of the transaction. The arrangement agreement includes a US$3 million termination fee payable by C21 to Vireo Growth if C21 accepts a superior proposal, along with reciprocal expense reimbursement provisions in certain other termination scenarios.
